<DOC>
	<DOCNO>NCT01682408</DOCNO>
	<brief_summary>Study Assess Pharmacokinetics R406 Healthy Subjects Fostamatinib 150 mg Administered Alone Fed Fasted state Combination Ranitidine Fasted State , Assess Relative Bioavailability Process Variants Tablets</brief_summary>
	<brief_title>Assess Pharmacokinetics Fostamatinib Fed Fasted State Combination With Ranitidine Assess Bioavailability</brief_title>
	<detailed_description>An Open-label , Single-center , 2-Part , Randomized Study Assess Pharmacokinetics R406 Healthy Subjects Fostamatinib 150 mg Administered Alone Fed Fasted state Combination Ranitidine Fasted State , Assess Relative Bioavailability Process Variants Tablets</detailed_description>
	<mesh_term>Mannitol</mesh_term>
	<mesh_term>Ranitidine</mesh_term>
	<mesh_term>Ranitidine bismuth citrate</mesh_term>
	<criteria>Provision sign date , write informed consent prior studyspecific procedure include genetic sampling analyse Volunteers male female age 18 55 year ( inclusive ) weight least 50 kg body mass index ( BMI ) 18 30 kg/m2 inclusive . Provision sign , write , date informed consent optional genetic research . If volunteer decline participate genetic component study , penalty loss benefit volunteer . Male volunteer willing use barrier contraception , ie , condom day first dose 2 week dose IP Treatment Period 5 . Females must negative pregnancy test screen admission CPU ( include checkin treatment period ) , must lactate must non childbearing potential , confirmed screen History clinically significant disease disorder , opinion Investigator , may either put volunteer risk participation study , influence result volunteer 's ability participate study History presence GI , hepatic , renal disease condition know interfere absorption , distribution , metabolism , excretion drug Any clinically significant illness , medical/surgical procedure , trauma within 4 week first administration IP Any clinically significant abnormality clinical chemistry , hematology , urinalysis result judge Investigator Any positive result screen serum hepatitis B surface antigen , hepatitis C antibody , human immunodeficiency virus ( HIV )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>R406 ,</keyword>
	<keyword>Fostamatinib ,</keyword>
	<keyword>Phase I ,</keyword>
	<keyword>Healthy Subjects ,</keyword>
	<keyword>Pharmacokinetics ,</keyword>
	<keyword>Fed/Fasted</keyword>
</DOC>